All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
On Sunday 3rd June an oral abstract session took place at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract 7505 was presented by Jeremy Abramson, Massachusetts General Hospital Cancer Center, Boston, on the updated safety and long term results of the TRANSCEND NHL 001 trial. This was a pivotal trial of the CAR-T therapy (NCT02631044), lisocabtagene maraleucel (JCAR017), in patients with relapsed/refractory (R/R) aggressive non-Hodgkin lymphoma (NHL).
The multicenter trial included three dose-finding cohorts that was expanded into two dose-expansion cohorts and then a pivotal diffuse large B-cell lymphoma (DLBCL) cohort. In total, 102 patients met the full specifications and were included in the study. Additional patients were included in the dose-finding and dose-escalation cohorts including patients with DLBCL that was transformed from chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), or primary mediastinal large cell lymphoma (PMBCL).
Professor Abramson concluded by saying that “lisocabtagene maraleucel is a CD19-directed CAR T-cell product administered with a defined composition and induced durable responses in high-risk patients with relapsed, refractory aggressive NHL. We see encouraging durable response rates six months and beyond in our core DLBCL dataset population. That includes 49% of patients in ongoing response at six months, and most of those in ongoing complete remission.”
He further added that 93% of patients who achieved the six-month time point, across all dose levels, remained in remission at the last follow up. Based on these findings, lisocabtagene maraleucel is safe with low toxicity.
The study is ongoing to evaluate lisocabtagene maraleucel for outpatient administration, including the pivotal cohort.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox